Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-7101
- Development stage
- Unknown
- Lead developer
- G2GBio
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
GB-7101 is a long-acting injectable formulation of leuprorelin acetate, a synthetic nonapeptide and gonadotropin-releasing hormone (GnRH) receptor agonist, developed by G2G Bio for the treatment of prostate cancer. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology, which encapsulates the active ingredient in biodegradable microspheres to provide sustained therapeutic levels over one-month (1M) or three-month (3M) intervals. Upon administration, leuprorelin initially stimulates the pituitary GnRH receptors, causing a transient increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, continuous exposure leads to the downregulation and desensitization of these receptors, resulting in a profound suppression of LH and FSH secretion. This subsequently reduces serum testosterone to castrate levels, thereby inhibiting the growth of androgen-sensitive prostate cancer cells.
- Other names
- Leuprorelin acetate sustained-release (G2G Bio)Leuprolide acetate sustained-release (G2G Bio)
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on GB-7101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-7101.